drugset / Trial / NCT04507750
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to explore the effectiveness and safety of camrelizumab combined with apatinib mesylate in the treatment of relapsed platinum-resistant epithelial ovarian cancer
Timeline
- Start
- 2020-08-10
- Primary completion
- 2021-08-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
Indications
No indication recorded.